RxDoctor Payments Data

Renee Johnson, APRN

Nurse Practitioner · Topeka, KSNPI 1902037054

Payments from drug & device makers

$704in general payments, 2019–2025

Across 17 payments — averaging $41.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$247
  • Insulet Corporation$131
  • Mannkind Corporation$128
  • Boehringer Ingelheim$123
  • Novo Nordisk$32
  • AbbVie$16
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$49170%
  • Education$15422%
  • Gifts$598%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$704 in reported general payments places this provider in the 70th percentile of 1,326 nurse practitioner providers in Kansas.

See all nurse practitioner providers in Kansas

Medicare billing

Part B allowed, 2024
$106,236
Medicare patients
410
Services billed
3,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide388$559,685
MounjaroTirzepatide287$399,090
JardianceEmpagliflozin279$293,831
TrulicityDulaglutide128$175,259
Tresiba Flextouch U-200Insulin Degludec109$108,551
Tresiba Flextouch U-100Insulin Degludec186$95,677
Fiasp FlextouchInsulin Aspart (Niacinamide)76$88,726
Humalog Kwikpen U-200Insulin Lispro22$83,718
FarxigaDapagliflozin Propanediol62$71,052
Novolog FlexpenInsulin Aspart173$45,154
Synjardy XrEmpagliflozin/Metformin Hcl48$44,814
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$31,308
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/746$30,688
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog72$22,949
Humalog Kwikpen U-100Insulin Lispro63$18,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog, Fiasp$32$585,715448 claims
Lilly USA, LLCMounjaro, Trulicity$12$574,349415 claims
Boehringer IngelheimJardiance, Synjardy Xr$123$338,646327 claims
AbbVieSynthroid$16$9,243114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,326 nurse practitioner providers in Kansas.

Other nurse practitioner in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →